IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
58.577,49 +3.240,95 (+5,86%)
CASI Pharmaceuticals, Inc. (CASI)
CASI Pharmaceuticals, Inc.
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road Chaoyang District
Beijing 100025
China
86 10 6508 6063
https://www.casipharmaceuticals.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 176
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Wei-Wu He Ph.D. | Chairman & CEO | 565,36k | N/A | 1965 |
| Dr. Wei Zhang Ph.D. | President | 1,13M | N/A | 1960 |
| Dr. Alexander A. Zukiwski M.D. | Executive VP & Chief Medical Officer | 514,79k | N/A | 1957 |
| Ms. Kun Qian | VP & Global Controller | N/A | N/A | 1982 |
| Ms. Chunhua Wang | Chief Operating Officer | N/A | N/A | 1972 |
| Ms. Wei Gao | General Counsel | N/A | N/A | 1981 |
| Dr. James E. Goldschmidt Ph.D. | Chief Business Development Officer | N/A | N/A | N/A |
| Mr. Hai Huang | Global Chief Commercial Officer | N/A | N/A | 1969 |
| Ms. Amanda Cui | VP & Global Controller | N/A | N/A | N/A |
Descripción
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Gobierno corporativo
El ISS Governance QualityScore de CASI Pharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
